Peptide price index
-4.6%
Comparing the same vendor and peptide then and now, 64 vendors that pass our metascore cutoff (75+) cut single-vial prices by 4.6% on average, from Oct 7, 2026 – Oct 23, 2026 to their latest reading (Nov 9, 2026 – Nov 20, 2026). Of 1987 vendor and peptide pairs, 428 got cheaper by more than 2% and 169 got dearer; the rest held.
Rebuilt from our price history on every site update; newest prices read Nov 20, 2026. Download the numbers (JSON).
By peptide
Peptides with at least 8 vendors priced both then and now, most widely sold first.
| Peptide | Change | Cheaper | Dearer | Vendors | Median now, per mg |
|---|---|---|---|---|---|
| GHK-Cu | -5.6% | 17 | 5 | 60 | $0.517 |
| Tesamorelin | -5.9% | 16 | 4 | 57 | $6.00 |
| BPC-157 | -6.5% | 15 | 4 | 56 | $4.10 |
| MOTS-c | -5.0% | 14 | 3 | 56 | $2.75 |
| Retatrutide | -9.7% | 22 | 6 | 55 | $4.00 |
| NAD+ | -4.8% | 11 | 4 | 51 | $0.095 |
| TB-500 | -3.3% | 8 | 6 | 51 | $5.50 |
| KLOW | -3.7% | 10 | 4 | 50 | $1.23 |
| BPC-157 + TB-500 | -4.4% | 12 | 3 | 48 | $4.56 |
| Tirzepatide | -8.2% | 16 | 6 | 48 | $2.41 |
| Ipamorelin | -3.0% | 9 | 6 | 47 | $5.00 |
| KPV | -4.2% | 8 | 6 | 47 | $4.30 |
| DSIP | -5.5% | 9 | 3 | 46 | $5.28 |
| GLOW | -2.5% | 6 | 4 | 46 | $1.29 |
| Selank | -4.5% | 8 | 4 | 46 | $4.00 |
| Semax | -4.8% | 8 | 3 | 46 | $3.80 |
| Melanotan II | -4.5% | 10 | 4 | 45 | $3.50 |
| CJC-1295 (no DAC) + Ipamorelin | -4.4% | 6 | 1 | 44 | $5.20 |
| Epithalon | -4.2% | 9 | 5 | 42 | $2.57 |
| PT-141 | -3.7% | 10 | 3 | 42 | $3.75 |
| Cagrilintide | -5.5% | 10 | 3 | 41 | $8.80 |
| AOD-9604 | -3.9% | 9 | 3 | 38 | $8.85 |
| Sermorelin | -2.4% | 4 | 3 | 35 | $6.50 |
| Thymosin Alpha-1 | -3.9% | 10 | 2 | 35 | $7.20 |
| Kisspeptin-10 | -5.5% | 8 | 4 | 34 | $4.50 |
| SS-31 | -4.1% | 7 | 4 | 34 | $3.32 |
| Semaglutide | -7.4% | 12 | 4 | 33 | $4.90 |
| 5-Amino-1MQ | -4.9% | 8 | 2 | 32 | $1.51 |
| CJC-1295 (no DAC) | -5.7% | 6 | 2 | 32 | $6.80 |
| Glutathione | -2.3% | 7 | 4 | 31 | $0.040 |
| IGF-1 LR3 | -3.0% | 5 | 3 | 31 | $75.00 |
| Melanotan I | -6.8% | 7 | 1 | 27 | $3.00 |
| Snap-8 | -3.6% | 5 | 3 | 27 | $3.30 |
| LL-37 | -2.2% | 4 | 3 | 26 | $9.00 |
| ARA-290 | -3.3% | 4 | 1 | 24 | $4.74 |
| VIP | -5.1% | 7 | 2 | 24 | $6.71 |
| Ipamorelin + Tesamorelin | -6.8% | 7 | 2 | 23 | $6.43 |
| Pinealon | -7.3% | 5 | 0 | 23 | $3.05 |
| CJC-1295 with DAC | -3.9% | 3 | 1 | 22 | $9.45 |
| Cartalax | -4.3% | 5 | 2 | 20 | $2.75 |
| FOXO4-DRI | -3.5% | 4 | 2 | 19 | $13.20 |
| Oxytocin | -4.0% | 4 | 3 | 19 | $4.99 |
| Adamax | -1.1% | 2 | 3 | 15 | $6.90 |
| Hexarelin | -5.6% | 2 | 0 | 15 | $8.00 |
| Selank + Semax | -9.2% | 5 | 0 | 14 | $4.00 |
| GHRP-2 | +1.9% | 0 | 1 | 12 | $4.40 |
| PE-22-28 | -0.5% | 2 | 1 | 12 | $5.00 |
| Cagrilintide + Semaglutide | -1.5% | 1 | 0 | 11 | $10.90 |
| GHRP-6 | -2.1% | 1 | 0 | 11 | $4.80 |
| Cagrilintide + Retatrutide | -9.5% | 5 | 0 | 10 | $7.64 |
| GHK-Cu + KPV | -6.7% | 2 | 0 | 10 | $1.14 |
| AHK-Cu | -9.4% | 3 | 1 | 9 | $0.500 |
| AICAR | +1.8% | 1 | 1 | 9 | $1.00 |
| SLU-PP-332 | -5.1% | 2 | 2 | 9 | $9.20 |
| Survodutide | -2.2% | 2 | 0 | 9 | $12.42 |
| Cardiogen | +6.6% | 0 | 2 | 8 | $2.75 |
| Thymalin | +4.9% | 1 | 2 | 8 | $4.30 |
How this is measured
The index follows the same vendor and peptide over time, so it measures price changes rather than which vendors happen to be in the data. Listings are single vials, in stock, from vendors with a metascore of 75 or more; prices the app flags as outliers (usually a vial-count mistake) and moves larger than 60% down or 150% up (data errors) are left out. "Cheaper" and "dearer" count vendors whose price moved by more than 2%. Shipping, coupons and multi-vial kits are not included. Cheapest is not the same as best: see each vendor's lab tests on its page.
Peptide prices: questions
Are peptide prices going up or down?
Down, on average, in our latest reading: -4.6% over 4 weeks across 64 vendors.
How is the PeptideCompare price index calculated?
For every vendor and peptide we compare the cheapest price per mg for a single vial on the vendor's latest reading with its price at least 28 days earlier, then average those changes (geometric mean). Only vendors that pass our metascore cutoff and in-stock listings count, and a vendor joining or leaving the data cannot move the index.